Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Care Policy and Evaluation Centre (CPEC), London School of Economics and Political Science, London, UK; 2 School for Social Care Research, National Institute for Health Research, UK; 3 Department of Social Work and Social Administration, University of Hong Kong, Hong Kong
Список исп. литературыСкрыть список 1. Knapp M. Economic evaluation and mental health: sparse past… fertile future?J Ment Health Policy Econ 1999;2:163-7. 2. Drummond MF, Sculpher MJ, Claxton K et al. Methods for the economicevaluation of health care programmes, 4th ed. Oxford: Oxford Medical Publications, 2015. 3. Cookson R, Mirelman AJ, Griffin S et al. Using cost-effectiveness analysis to address health equity concerns. Value Health 2017;20:206-12. 4. Knapp M, Iemmi V. Mental health. In: Scheffler RM (ed). World scientific handbook of global health economics and public policy, Vol. 2. Singapore: World Scientific, 2016:1-41. 5. Bloom DE, Cafiero ET, Janй-Llopis E et al. The global economic burden of noncommunicable diseases. Geneva: World Economic Forum, 2011. 6. Knapp M, Iemmi V. Noncommunicable disease: the case of mental health, macroeconomic effect of. In: Culyer AJ (ed). Encyclopedia of health economics, 2014:366-9. 7. Knapp M, Iemmi V. The role of economics in mental health policy. In: Davidson L (ed). The Routledge handbook of international development, mental health and wellbeing. Abingdon-on-Thames: Routledge, 2019. 8. Martin-Carrasco M, Evans-Lacko S, Dom G et al. EPA guidance on mental health and economic crises in Europe. Eur Arch Psychiatry Clin Neurosci 2016;266:89-124. 9. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London: National Institute for Health and Care Excellence, 2013. 10. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness – the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7. 11. World Health Organization. Making the investment case for mental health: a WHO/UNDP methodological guidance note. Geneva: World Health Organization, 2019. 12. World Health Organization. Mental health atlas 2017. Geneva: World Health Organization, 2018. 13. Vigo DV, Kestel D, Pendakur K et al. Disease burden and government spending on mental, neurological, and substance use disorders, and self-harm: cross-sectional, ecological study of health system response in the Americas. Lancet Public Health 2019;4:e89-96. 14. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 2010;6:98-103. 15. World Health Organization. Dementia: a public health priority. Geneva: World Health Organization, 2012. 16. Alzheimer’s Disease International. Policy brief for heads of government: the global impact of dementia 2013-2050. London: Alzheimer’s Disease International, 2013. 17. Camacho EM, Shields GE. Cost-effectiveness of interventions for perinatal anxiety and/or depression: a systematic review. BMJ Open 2018;8: e022022. 18. Wilkinson A, Anderson S, Wheeler SB. Screening for and treating postpartum depression and psychosis: a cost-effectiveness analysis. Matern Child Health J 2017;21:903-14. 19. Morrell CJ, Warner R, Slade P et al. Psychological interventions for postnatal depression: cluster randomised trial and economic evaluation. The PoNDER trial. Health Technol Assess 2009;13:iii-iv, xi-xiii, 1-153. 20. Bauer A, Pawlby S, Plant DT et al. Perinatal depression and child development: exploring the economic consequences from a South London cohort. Psychol Med 2015;45:51-61. 21. Bauer A, Parsonage M, Knapp M et al. The costs of perinatal mental health problems. London: Centre for Mental Health and London School of Economics, 2014. 22. Bauer A, Knapp M, Adelaja B. Best practice for perinatal mental health care: the economic case. London: London School of Economics and Political Science, 2016. 23. Morrell CJ, Sutcliffe P, Booth A et al. A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. Health Technol Assess 2016;20:1-414. 24. Henderson C, Dixon S, Bauer A et al. Cost-effectiveness of PoNDER health visitor training for mothers at lower risk of depression: findings on prevention of postnatal depression from a cluster-randomised controlled trial. Psychol Med 2019;49:1324-34. 25. Paulden M, Palmer S, Hewitt C et al. Screening for postnatal depression in primary care: cost effectiveness analysis. BMJ 2009;339:b5203. 26. Clarke K, King M, Prost A. Psychosocial interventions for perinatal common mental disorders delivered by providers who are not mental health specialists in low- and middle-income countries: a systematic review and metaanalysis. PLoS Med 2013;10:e1001541. 27. Hamilton MP, Hetrick SE, Mihalopoulos C et al. Identifying attributes of care that may improve cost-effectiveness in the youth mental health service system. Med J Aust 2017;207:S27-37. 28. Beecham J. Annual research review: Child and adolescent mental health interventions: a review of progress in economic studies across different disorders. J Child Psychol Psychiatry 2014;55:714-32. 29. Patton GC, Sawyer SM, Santelli JS et al. Our future: a Lancet commission on adolescent health and wellbeing. Lancet 2016;387:2423-78. 30. Knapp M, Ardino V, Brimblecombe N et al. Youth mental health: new economic evidence. London: London School of Economics and Political Science 2016. 31. Byford S, Barrett B, Roberts C et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression. Br J Psychiatry 2007;191:521-7. 32. Domino ME, Foster EM, Vitiello B et al. Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry 2009;48:711-20. 33. Brettschneider C, Djadran H, Harter M et al. Cost-utility analyses of cognitive- behavioural therapy of depression: a systematic review. Psychother Psychosom 2015;84:6-21. 34. Dickerson JF, Lynch FL, Leo MC et al. Cost-effectiveness of cognitive behavioral therapy for depressed youth declining antidepressants. Pediatrics 2018;141:e20171969. 35. Domino ME, Burns BJ, Silva SG et al. Cost-effectiveness of treatments foradolescent depression: results from TADS. Am J Psychiatry 2008;165:588- 96. 36. Evans-Lacko S, Takizawa R, Brimblecombe N et al. Childhood bullying victimization is associated with use of mental health services over five decades: a longitudinal nationally representative cohort study. Psychol Med 2017;47:127-35. 37. Brimblecombe N, Evans-Lacko S, Knapp M et al. Long term economic impact associated with childhood bullying victimisation. Soc Sci Med 2018;208:134-41. 38. Lamsal R, Zwicker JD. Economic evaluation of interventions for children with neurodevelopmental disorders: opportunities and challenges. Appl Health Econ Health Policy 2017;15:763-72. 39. Skokauskas N, Lavelle TA, Munir K et al. The cost of child and adolescent mental health services. Lancet Psychiatry 2018;5:299-300. 40. Hilferty F, Cassells R, Muir K et al. Is headspace making a difference to young people’s lives? Final report of the independent evaluation of the headspace program. Sydney: Social Policy Research Centre, UNSW Australia, 2015. 41. Singh SP, Tuomainen H, de Girolamo G et al. Protocol for a cohort study of adolescent mental health service users with a nested cluster randomized controlled trial to assess the clinical and cost-effectiveness of managed transition in improving transitions from child to adult mental health services (the MILESTONE study). BMJ Open 2017;7:e016055. 42. Richards DA, Ekers D, McMillan D et al. Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet 2016;388:871-80. 43. Ho FY, Yeung WF, Ng TH et al. The efficacy and cost-effectiveness of stepped care prevention and treatment for depressive and/or anxiety disorders: a systematic review and meta-analysis. Sci Rep 2016;6:29281. 44. Grochtdreis T, Brettschneider C, Wegener A et al. Cost-effectiveness of collaborative care for the treatment of depressive disorders in primary care: a systematic review. PLoS One 2015;10:e0123078. 45. Chisholm D, Sweeny K, Sheehan P et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry 2016;3:415-24. 46. Layard R, Clark DM. Why more psychological therapy would cost nothing. Front Psychol 2015;6:1713. 47. Randall JR, Vokey S, Loewen H et al. A systematic review of the effect of early interventions for psychosis on the usage of inpatient services. Schizophr Bull 2015;41:1379-86. 48. Bird V, Premkumar P, Kendall T et al. Early intervention services, cognitivebehavioural therapy and family intervention in early psychosis: systematic review. Br J Psychiatry 2010;197:350 6. 49. Correll CU, Galling B, Pawar A et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry 2018;75:555-65. 50. Knapp M, Andrew A, McDaid D et al. Making the business case for effective interventions for people with schizophrenia and psychosis. London: London School of Economics and Political Science, 2014. 51. Park AL, McCrone P, Knapp M. Early intervention for first-episode psychosis: broadening the scope of economic estimates. Early Interv Psychiatry 2016;10:144-51. 52. Aceituno D, Vera N, Prina AM et al. Cost-effectiveness of early intervention in psychosis: systematic review. Br J Psychiatry 2019;215:388-94. 53. Behan C, Masterson S, Clarke M. Systematic review of the evidence for service models delivering early intervention in psychosis outside the standalone centre. Early Interv Psychiatry 2017;11:3-13. 54. Health Quality Ontario. Cognitive behavioural therapy for psychosis: a health technology assessment. Ont Health Technol Assess Ser 2018;18:1-141. 55. Henderson C, Knapp M, Yeeles K et al. Cost-effectiveness of financial incentives to promote adherence to depot antipsychotic medication: economic evaluation of a cluster-randomised controlled trial. PLoS One 2015; 10:e0138816. 56. Knapp M, Patel A, Curran C et al. Supported employment: cost-effectiveness across six European sites. World Psychiatry 2013;12:60-8. 57. Bond GR, Drake RE, Becker DR. Generalizability of the individual placement and support (IPS) model of supported employment outside the US. World Psychiatry 2012;11:32-9. 58. Knapp M, McDaid D, Park AL. Recovery and economics. Die Psychiatrie 2015;12:162-6. 59. Nemeth B, Fasseeh A, Molnar A et al. A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Rev Pharmacoecon Outcomes Res 2018;18:267-75. 60. Wimo A, Ballard C, Brayne C et al. Health economic evaluation of treatments for Alzheimer’s disease: impact of new diagnostic criteria. J Intern Med 2014;275:304-16. 61. Peters JL, Anderson R, Hoyle M et al. Evolution of a cost-utility model of donepezil for Alzheimer’s disease. Int J Technol Assess Health Care 2013;29:147- 54. 62. Knapp M, King D, Romeo R et al. Cost-effectiveness ofdonepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial). Int J Geriatr Psychiatry 2017;32:1205-16. 63. Howard R, McShane R, Lindesay J et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO- AD) trial: secondary and post-hoc analyses. Lancet Neurol 2015;14: 1171-81. 64. Banerjee S, Hellier J, Dewey M et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo- controlled trial. Lancet 2011;378:403-11. 65. Romeo R, Knapp M, Hellier J et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. Br J Psychiatry 2013;202:121-8. 66. Rosenheck RA, Leslie DL, Sindelar JL et al. Cost-benefit analysis of secondgeneration antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry 2007;64:1259-68. 67. National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. London: National Institute for Health and Care Excellence, 2018. 68. Knapp M, Thorgrimsen L, Patel A et al. Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis. Br J Psychiatry 2006;188:574- 80. 69. D’Amico F, Rehill A, Knapp M et al. Maintenance cognitive stimulation therapy: an economic evaluation within a randomized controlled trial. J Am Med Dir Assoc 2015;16:63-70. 70. Brown H, D’Amico F, Knapp M et al. A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements. Aging Ment Health 2019;23:602-7. 71. Department of Health and Social Care. Prime Minister’s challenge on dementia 2020. London: Department of Health and Social Care, 2015. 72. Knapp M, King D, Romeo R et al. Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrAtegies for RelaTives) study): a pragmatic randomised controlled trial. BMJ 2013;347:f6342. 73. Livingston G, Manela M, O’Keeffe A et al. Clinical effectiveness of the START (STrAtegies for RelaTives) psychological intervention for family carers and the effects on the cost of care for people with dementia: 6-year follow-up of a randomised controlled trial. Br J Psychiatry (in press). 74. Nichols LO, Chang C, Lummus A et al. The cost-effectiveness of a behavior intervention with caregivers of patients with Alzheimer’s disease. J Am Geriatr Soc 2008;56:413-20. 75. Lykens K, Moayad N, Biswas S et al. Impact of a community based implementation of REACH II program for caregivers of Alzheimer’s patients. PLoS One 2014;9:e89290. 76. Michalowsky B, Xie F, Eichler T et al. Cost-effectiveness of a collaborative dementia care management – Results of a cluster-randomized controlled trial. Alzheimers Dement 2019;15:1296-308. 77. Livingston G, Barber J, Marston L et al. Clinical and cost-effectiveness of the Managing Agitation and Raising Quality of Life (MARQUE) intervention for agitation in people with dementia in care homes: a single-blind, cluster-randomised controlled trial. Lancet Psychiatry 2019;6:293-304. 78. Romeo R, Zala D, Knapp M et al. Improving the quality of life of care home residents with dementia: cost-effectiveness of an optimized intervention for residents with clinically significant agitation in dementia. Alzheimers Dement 2019;15:282-91. 79. Ballard C, Corbett A, Orrell M et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial. PLoS Med 2018;15:e1002500. 80. Patel V, Chisholm D, Parikh R et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd ed. Lancet 2016;387:1672-85. 81. Arango C, Diaz-Caneja CM, McGorry PD et al. Preventive strategies for mental health. Lancet Psychiatry 2018;5:591-604. 82. Thornicroft G, Mehta N, Clement S et al. Evidence for effective interventions to reduce mental-health-related stigma and discrimination. Lancet2016;387:1123-32. 83. Simon G, Katon W, Lin E et al. Diabetes complications and depression aspredictors of health service costs. Gen Hosp Psychiatry 2005;27:344-51. 84. Snell T, Knapp M, Healey A et al. Economic impact of childhood psychiatric disorder on public sector services in Britain: estimates from national survey data. J Child Psychol Psychiatry 2013;54:977-85. 85. Woo JM, Kim W, Hwang TY et al. Impact of depression on work productivity and its improvement after outpatient treatment with antidepressants. Value Health 2011;14:475-82. 86. Scott S, Knapp M, Henderson J et al. Financial cost of social exclusion: follow up study of antisocial children into adulthood. BMJ 2001;323:191. 87. Knapp M, McDaid D, Parsonage M. Mental health promotion and mental illness prevention: the economic case. London: London School of Economics and Political Science, 2011. 88. McDaid D, Park AL, Knapp M. Commissioning cost-effective services for promotion of mental health and wellbeing and prevention of mental illhealth. London: London School of Economics and Political Science, 2017. 89. Funk M, Drew N, Knapp M. Mental health, poverty and development. J Public Ment Health 2012;11:166-85. 90. Lund C, De Silva M, Plagerson S et al. Poverty and mental disorders: breaking the cycle in low-income and middle-income countries. Lancet 2011;378: 1502-14. 91. Naylor C, Parsonage M, McDaid D et al. Long-term conditions and mental health: the cost of co-morbidities. London: The King’s Fund, 2012. 92. Patel V, Saxena S, Lund C et al. The Lancet commission on global mental health and sustainable development. Lancet 2018;392:1553-98. 93. Kilbourne AM, Beck K, Spaeth-Rublee B et al. Measuring and improving the quality of mental health care: a global perspective. World Psychiatry 2018; 17:30-8. 94. Webber M, Treacy S, Carr S et al. The effectiveness of personal budgets for people with mental health problems: a systematic review. J Ment Health 2014;23:146-55.